IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC )
Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves' Disease.
| Ticker |
Sentiment |
Impact |
|
IMVT
|
Somewhat Bullish
|
69 %
|
|
KRYS
|
Somewhat Bullish
|
20 %
|
|
ILMN
|
Somewhat Bullish
|
15 %
|
|
FULC
|
Neutral
|
20 %
|
